The immune response to Prevotella bacteria in chronic inflammatory disease
Иммунный ответ на бактерии Prevotella при хронических воспалительных заболеваниях
2017-05-23
SCID: 54.1/d9kxmuec
Discuss with AI
PrevotellaTh17-mediated mucosal inflammationToll-like receptor 2 (TLR2) activationinterleukin-23 (IL-23) and IL-1 productionmucosal microbiota dysbiosis in chronic inflammatory disease
Figures from the paper
Abstract (AI)
The microbiota plays a central role in human health and disease by shaping immune development, immune responses and metabolism, and by protecting from invading pathogens. Technical advances that allow comprehensive characterization of microbial communities by genetic sequencing have sparked the hunt for disease-modulating bacteria. Emerging studies in humans have linked the increased abundance of Prevotella species at mucosal sites to localized and systemic disease, including periodontitis, bacterial vaginosis, rheumatoid arthritis, metabolic disorders and low-grade systemic inflammation. Intriguingly, Prevotella abundance is reduced within the lung microbiota of patients with asthma and chronic obstructive pulmonary disease. Increased Prevotella abundance is associated with augmented T helper type 17 (Th17) -mediated mucosal inflammation, which is in line with the marked capacity of Prevotella in driving Th17 immune responses in vitro. Studies indicate that Prevotella predominantly activate Toll-like receptor 2, leading to production of Th17-polarizing cytokines by antigen-presenting cells, including interleukin-23 (IL-23) and IL-1. Furthermore, Prevotella stimulate epithelial cells to produce IL-8, IL-6 and CCL20, which can promote mucosal Th17 immune responses and neutrophil recruitment. Prevotella-mediated mucosal inflammation leads to systemic dissemination of inflammatory mediators, bacteria and bacterial products, which in turn may affect systemic disease outcomes. Studies in mice support a causal role of Prevotella as colonization experiments promote clinical and inflammatory features of human disease. When compared with strict commensal bacteria, Prevotella exhibit increased inflammatory properties, as demonstrated by augmented release of inflammatory mediators from immune cells and various stromal cells. These findings indicate that some Prevotella strains may be clinically important pathobionts that can participate in human disease by promoting chronic inflammation.
Key Findings
1
Increased abundance of Prevotella species at mucosal sites is linked to localized and systemic diseases including periodontitis, bacterial vaginosis, rheumatoid arthritis, metabolic disorders, and low-grade systemic inflammation.
2
Mouse colonization experiments support a causal role for Prevotella in promoting clinical and inflammatory features of human disease, and some Prevotella strains act as pathobionts with increased inflammatory properties versus strict commensals.
3
Prevotella abundance is reduced in the lung microbiota of patients with asthma and chronic obstructive pulmonary disease, contrasting with increases at other mucosal sites.
4
Prevotella predominantly activate Toll-like receptor 2 on antigen-presenting cells, inducing production of Th17-polarizing cytokines such as IL-23 and IL-1, and stimulate epithelial cells to produce IL-8, IL-6, and CCL20.
5
Prevotella promote augmented Th17-mediated mucosal inflammation and strongly drive Th17 immune responses in vitro.
Research Object
Prevotella bacteria (mucosal Prevotella species in humans)
Research Subject
Prevotella-driven immune responses and inflammation mechanisms, particularly Th17-polarized mucosal immunity, Toll-like receptor 2 activation, cytokine/chemokine production (IL-23, IL-1, IL-6, IL-8, CCL20), neutrophil recruitment, mucosal-to-systemic dissemination, and their role in chronic inflammatory diseases
Publication Details
Publication Date
2017-05-23
Journal
Publisher
ISSN
Open access PDF
Access Type
Author Information
Download PDF
Subscribe to digest